Health Economics›Esophageal squamous cell carcinoma›Metastatic or locally advanced disease first-line

Metastatic or locally advanced disease first-line

Esophageal squamous cell carcinoma · 25 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 6 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
mFOLFOX6 and Pembrolizumab Variant #01	—	R 170 413	42d	—	—	—	—	—
Cisplatin and Paclitaxel (TP) and Pembrolizumab Variant #01	—	R 83 451	21d	—	~26.4 mo	—	—	2
Cisplatin and Fluorouracil (CF) and Pembrolizumab Variant #01	—	R 82 937	21d	—	~12.5 mo	—	—	4
Ipilimumab and Nivolumab Variant #01 Partial	—	R 78 615	42d	—	12.7 mo	—	—	1
Cisplatin and Fluorouracil (CF) and Cetuximab Variant #01	—	R 74 819	21d	~5.5 mo	~10.9 mo	~8	~R 598 553 PFS proxy · indirect	5
Etoposide monotherapy Variant #01	—	R 2 872	28d	—	—	—	—	—
Cisplatin and Paclitaxel (TP) and Sintilimab Variant #01 Partial	—	R 2 803	28d	—	17.2 mo	—	—	1
Oxaliplatin, Paclitaxel, Tislelizumab Variant #01 Partial	—	R 2 612	21d	—	17.2 mo	—	—	—
Oxaliplatin and Paclitaxel Variant #01	—	R 2 612	21d	—	10.6 mo	—	—	—
CapeOx Variant #01	—	R 2 384	21d	—	10.6 mo	—	—	—
Fluorouracil and Oxaliplatin (FUOX) and Tislelizumab Variant #01 Partial	—	R 1 913	21d	—	17.2 mo	—	—	—
Cisplatin and Fluorouracil (CF) Variant #29	—	R 1 900	21d	5.4 mo	11.1 mo	8	R 15 201 PFS proxy	7
Cisplatin and Paclitaxel (TP) and Camrelizumab Variant #01 Partial	—	R 1 589	21d	6.9 mo	15.5 mo	11	R 17 477 PFS proxy	3
Cisplatin and Paclitaxel (TP) and Toripalimab Variant #01 Partial	—	R 1 589	21d	—	17.0 mo	—	—	1
Cisplatin and Paclitaxel (TP) and Tislelizumab Variant #01 Partial	—	R 1 514	21d	—	17.2 mo	—	—	—
Capecitabine and Cisplatin (CX) Variant #01	—	R 1 386	21d	—	10.6 mo	—	—	—
Capecitabine and Cisplatin (CX) and Tislelizumab Variant #01 Partial	—	R 1 286	21d	—	17.2 mo	—	—	—
FUOX Variant #01	—	R 1 223	14d	—	10.6 mo	—	—	—
Cisplatin and Fluorouracil (CF) and Nivolumab Variant #01 Partial	—	R 950	28d	—	13.2 mo	—	—	1
Cisplatin and Fluorouracil (CF) and Sintilimab Variant #01 Partial	—	R 925	28d	—	17.2 mo	—	—	1
Cisplatin and Fluorouracil (CF) and Sugemalimab Variant #01 Partial	—	R 840	21d	6.2 mo	15.3 mo	9	R 7 560 PFS proxy	2
Cisplatin and Fluorouracil (CF) and Tislelizumab Variant #01 Partial	—	R 816	21d	—	17.2 mo	—	—	—
Cisplatin and Paclitaxel (TP) Variant #01	—	R 716	10d	5.6 mo	11.1 mo	18	R 12 892 PFS proxy	5
Cisplatin and Docetaxel (DC) N/A - secondary systemic drug	—	R 449	21d	~24.0 mo	—	~35	~R 15 722 PFS proxy · indirect	1
Capecitabine and Oxaliplatin (CapeOx) and Tislelizumab Partial	—	—	—	—	17.2 mo	—	—	—

25 of 25 regimens shown